415 Capital Management
Widenmayerstrasse 15
|
80538
München
|
de
415 Capital Management
Profile
415 Capital Management GmbH is a specialist investment firm which invests in innovative medical device (“MedTech”) companies in Europe, the United States, and Israel. The firm primarily invests in novel technologies addressing cardiovascular disease, its risk factors and comorbidities. The 415 Capital team has funded over 50 MedTech startups over the past 25 years with successful exits including Claret Medical (sold to Boston Scientific), ReCor Medical (sold to Otsuka Holdings), ImThera Medical (sold to LivaNova), CardiAQ Valve Technologies (sold to Edwards Lifesciences), and CoreValve (sold to Medtronic).
Kontakt
Name of contact person
Frederik Groenewegen
eMail
Website:
INFO
| Managing Directors / Partners |
Frank Groenewegen David Thompson Frederik Groenewegen |
| Shareholders |
Frank Groenewegen David Thompson Frederik Groenewegen |
| Professionals | 415 Capital Management GmbH |
| Fund Count | 2 |
| Capital | € 100 m |
| Portfolio Companies | 10-15 |
| Investment Type | Unabhängige Beteiligungsgesellschaft |
| Equity / Investment range | 4.000 Mio. € - 10.000 Mio. € |
| Transaction volume | 1 Mio. € - 5 Mio. € |
| Equity Type | Minderheitsbeteiligung |
| Investment Reasons |
Seed-Finanzierung Start up-Finanzierung Expansions- / Wachstumsfinanzierung Bridge- / vorbörsliche Finanzierung |
| Industry sector |
Medizin - Healthcare Medizintechnik |
| Geographical Focus |
Deutschland Deutschsprachiger Raum (DACH) Westeuropa USA Israel |